Ozempic and Wegovy contain the same active ingredient, semaglutide.1,2 Both are once-weekly subcutaneous injections made by Novo Nordisk.3 Their U.S. Food and Drug Administration (FDA) labels authorize different uses. Ozempic centers on type 2 diabetes and related outcomes. Wegovy includes chronic weight management. If your goal is weight loss without type 2 diabetes, Wegovy carries the direct FDA indication, while your physician still needs to weigh your medical history and coverage.
One Active Ingredient Under Two FDA Labels
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Ozempic and Wegovy deliver that same active ingredient under separate product labels.1,2
The distinction starts with the FDA-approved indication. An indication is the disease or condition the FDA has approved a drug to treat.
The Ozempic prescribing information lists three uses. These include improving glycemic control in adults with type 2 diabetes, reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing kidney disease progression in adults with type 2 diabetes and chronic kidney disease.1
Ozempic does not carry an FDA-approved weight-loss indication. A prescription intended only for weight loss in someone without type 2 diabetes therefore falls outside the Ozempic label.
The Wegovy prescribing information includes chronic weight management in adults with obesity. It also covers adults with overweight and at least one weight-related condition.2 The weight-management indication extends to adolescents aged 12 years and older with obesity.2
Wegovy also carries indications for cardiovascular risk reduction in certain adults and treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.2 MASH is a liver condition associated with fat accumulation, inflammation, and liver damage.
Your diagnosis determines which label fits. The brand name alone does not answer that question.
FDA-Approved Uses, Doses, and Pen Strengths at a Glance
The Ozempic vs Wegovy comparison comes down to approved use, available pen strengths, and the dose ceiling stated in each label.
| Product | FDA-Approved Indication | Maintenance Dose Ceiling | Pen Strengths Available | Typical Use Case |
|---|---|---|---|---|
| Ozempic | Glycemic control in adults with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease; kidney disease risk reduction in adults with type 2 diabetes and chronic kidney disease.1 | 2 mg weekly.1 | Pens delivering 0.25 or 0.5 mg, 1 mg, and 2 mg doses.1 | An adult with type 2 diabetes whose treatment plan addresses blood glucose. The label also covers the specified cardiovascular and kidney outcomes. |
| Wegovy | Long-term weight management in adults and eligible adolescents with obesity; weight management in adults with overweight and a weight-related condition; cardiovascular risk reduction in eligible adults; treatment of noncirrhotic MASH with moderate to advanced fibrosis in adults.2 | 2.4 mg weekly is the recommended maintenance dose. The label also allows 1.7 mg as a maintenance dose.2 | Single-dose pens delivering 0.25, 0.5, 1, 1.7, and 2.4 mg.2 | An adult who meets the labeled criteria for chronic weight management. Other uses depend on the cardiovascular and liver criteria in the label. |
Wegovy HD is a separate 7.2 mg semaglutide product. The FDA approval applies after a patient has tolerated the 2.4 mg dosage for at least four weeks and a clinician determines that further weight reduction is indicated.4 That condition comes from the approval announcement and should not be read as personal dosing guidance.
The dose ceilings also explain why the two products should not be treated as interchangeable pens. Your prescriber selects a product and dose from the diagnosis, label, tolerance, current medications, and treatment goal.
Approved Uses for Weight Management
Wegovy carries the direct weight-management indication when you meet the criteria in its FDA label.2 That includes adults with obesity and adults with overweight plus at least one weight-related condition.
Ozempic’s approved uses remain tied to type 2 diabetes.1 Weight change may occur during diabetes treatment, but that does not create a weight-loss indication for the product.
On-label prescribing means the drug is prescribed for an indication listed in its FDA-approved labeling. Off-label prescribing means a physician uses an approved drug for a purpose outside that labeling.
A doctor can prescribe Ozempic off label for weight loss. That decision belongs to the prescribing physician, who weighs your diagnosis, medical history, other medications, potential adverse effects, and follow-up needs. It should not be treated as a shortcut to a preferred brand.
A physician matches the product to your diagnosis rather than to a preference: the Wegovy label applies when the goal is chronic weight management without type 2 diabetes, and the Ozempic label applies when type 2 diabetes is part of the picture. Your physician confirms which label fits before writing anything.
For the broader evidence on GLP-1 treatment and male health, see GLP-1 treatment for men.
Evidence from SUSTAIN-6 and STEP 1
SUSTAIN-6 and STEP 1 studied different populations and answered different questions. Combining their findings can make Ozempic and Wegovy look more interchangeable than the evidence supports.
SUSTAIN-6 Cardiovascular Findings
SUSTAIN-6 evaluated cardiovascular outcomes in 3,297 people with type 2 diabetes and high cardiovascular risk.5 Participants received semaglutide at 0.5 mg or 1 mg weekly, or placebo, for 104 weeks.5
The combined rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was lower with semaglutide. The reported hazard ratio was 0.74, with a 95% confidence interval of 0.58 to 0.95.5
SUSTAIN-6 was a cardiovascular-outcomes trial in type 2 diabetes. It does not establish the expected weight-loss effect of Wegovy at 2.4 mg.
STEP 1 Weight-Loss Findings
STEP 1 evaluated semaglutide for weight management in 1,961 adults without diabetes.6 Participants had a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition.6
The trial compared semaglutide 2.4 mg with placebo, alongside lifestyle intervention, over 68 weeks. Mean body-weight change was 14.9% lower in the semaglutide group and 2.4% lower in the placebo group.6 In the semaglutide group, 86% of participants lost at least 5% of their body weight.6
STEP 1 supports semaglutide’s weight-management evidence at the dose studied. It does not establish Ozempic’s diabetes or kidney indications.
Shared Adverse Reactions
Ozempic and Wegovy have overlapping adverse-reaction profiles because both contain semaglutide. Their labels list nausea, vomiting, diarrhea, constipation, and abdominal pain among the most common reactions.1,2
The lists are not identical. Wegovy’s label also names headache, fatigue, indigestion, dizziness, abdominal distension, belching, flatulence, gastroenteritis, acid reflux, and nasopharyngitis among reactions reported at the label’s common-reaction threshold.2 Hypoglycemia is also listed for patients with type 2 diabetes.2
Different labels, populations, and dose ranges make direct percentage comparisons difficult. Your physician should review symptoms in the context of your product, dose, medical history, and other medications.
The Wegovy label does not recommend taking it with another semaglutide-containing product or another GLP-1 receptor agonist.2 Give your prescriber a complete medication list before treatment decisions are made.
Insurance Coverage by Drug and Indication
Insurance coverage depends on the drug, the approved indication, and the terms of your plan. Coverage for diabetes treatment does not automatically extend to chronic weight management.
The Peterson-KFF Health System Tracker reported that 19% of firms with 200 or more workers covered GLP-1 drugs for weight loss in 2025.7 Among firms with 5,000 or more workers, coverage increased from 28% in 2024 to 43% in 2025.7
Those figures describe employer coverage for the drug class. They do not provide brand-specific coverage rates for Ozempic or Wegovy.
Before your appointment, obtain the formulary terms for both products and the coverage rules for your diagnosis. Your physician can then discuss the clinical fit without guessing what your plan will pay.
For self-pay, commercial insurance, and Medicare details, use the full GLP-1 cost and insurance breakdown.
A Physician-Led Product Decision
A useful prescription decision starts with your diagnosis and treatment goal. Your physician then considers the FDA label, medical history, current medications, previous treatment, adverse-effect risk, and insurance requirements.
Cardiovascular, kidney, and liver conditions can change the comparison because each label defines a different eligible population, so your physician re-checks the label against your full chart rather than against diagnosis alone.
This comparison is a poor fit if you want to choose a brand from a dose ceiling or online price alone. Bring your diagnosis, medication list, recent labs, and insurance formulary to a physician who can connect those facts.
The answer can also change if your diagnosis changes, your insurer updates its formulary, or a contraindication removes one product from consideration. Those changes require a new clinical review.
If you are comparing different active ingredients, see semaglutide vs tirzepatide.
The Opt Take on Semaglutide Selection
Opt Health treats the lab panel as the start of the decision. A physician reviews your results against your symptoms, medical history, current medications, body-composition goal, and insurance limits before building a treatment plan.
Follow-up matters because a prescription decision is not finished when the first pen arrives. Your response, adverse effects, and biomarkers need continued review. The plan can then be adjusted from measured results instead of assumptions.
That cycle is straightforward: test, interpret, treat, retest, and adjust.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are separate FDA-approved products.1,2 They have different labeled indications, pen presentations, and dose ceilings.
Ozempic’s indications center on type 2 diabetes and related cardiovascular and kidney outcomes. Wegovy carries the chronic weight-management indication for people who meet its label criteria.
A doctor can prescribe Ozempic off label for weight loss. Ozempic has no FDA-approved weight-loss indication, so using it specifically for that purpose falls outside its label.1
Your physician should make that decision from your medical history and treatment needs. You do not need to request a specific brand before the clinical review.
Coverage depends on your insurance plan and the indication attached to the prescription. A plan may cover Ozempic for type 2 diabetes while excluding Wegovy for weight management, or it may cover both under different authorization rules.
Ask your insurer for the formulary status and prior-authorization requirements for each product. Bring that information to your physician so coverage can be considered alongside clinical fit.
Ozempic has a maximum FDA-approved dose of 2 mg weekly.1 Standard Wegovy uses 2.4 mg as the recommended maintenance dose, while 1.7 mg is another labeled maintenance dose.2
Wegovy HD is a separate 7.2 mg product with its own use conditions.4 These label figures describe approved products and do not determine your personal dose.
Ozempic and Wegovy have similar common adverse reactions, including nausea, vomiting, diarrhea, constipation, and abdominal pain.1,2 Their label lists are not identical because the products were studied at different doses and in different populations.
Your experience cannot be predicted from the shared ingredient alone. Your physician should review adverse effects against the exact product and dose prescribed.
Both names appear because Ozempic and Wegovy contain semaglutide, and Ozempic may be prescribed off label for weight loss. Wegovy carries the direct FDA indication for chronic weight management in eligible patients.1,2
Use the Ozempic vs Wegovy label distinction to organize your questions, then let your physician match the product to your diagnosis, labs, medical history, and coverage.
References
- U.S. Food and Drug Administration. OZEMPIC (semaglutide) injection, for subcutaneous use: full prescribing information. Revised October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
- U.S. Food and Drug Administration. WEGOVY (semaglutide) injection, for subcutaneous use: full prescribing information. Revised October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s026lbl.pdf
- Novo Nordisk. Ozempic (semaglutide) approved in the US. Published December 5, 2017. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=712
- Novo Nordisk. FDA approves Novo Nordisk’s new Wegovy HD injection. Published March 19, 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Peterson-KFF Health System Tracker. Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss. Published October 22, 2025. https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.